AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
GlassWorm Supply-Chain Attack Abuses 72 Open VSX Extensions to Target Developers
Cybersecurity researchers have flagged a new iteration of the GlassWorm campaign that they say represents a “significant escalation” in how it propagates through the Open
